# GeoVax Labs, Inc. New (GOVX)

> GeoVax Labs, Inc. New (GOVX) trades at $1.81 (-5.24%) as of 7:59:59 PM EST on Nov 20, 2026, -64.54% over the past month. Market cap is $985.46K, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/govx
Data as of: 2026-11-21T00:59:59.653Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.81** -0.10 (-5.24%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$1.69** -0.12 (-6.63%)
As of 7:59:59 PM EST on Nov 20, 2026 · After hours

## Stock performance

How GeoVax Labs, Inc. New (GOVX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -5.24% |
| 1W | +6.16% |
| 1M | -64.54% |
| YTD | -98.24% |
| 1Y | -99.21% |
| 52-wk range | $1.51 – $270.66 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for GOVX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.75 – $1.95 |
| Open | $1.85 |
| Prev close | $1.91 |
| Volume | 4.23M |
| Market cap | $985.46K |
| Shares out | 544.45K |

## Valuation and profitability ratios

Valuation and profitability ratios for GeoVax Labs, Inc. New: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.86 |
| P/FCF | — |
| ROE | -1591.5% |
| ROA | -533.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[GeoVax Labs, Inc. New (GOVX) insider trading](https://massive.com/quote/govx/insider-trading.md): open-market Form 4 buys and sells by GeoVax Labs, Inc. New insiders over the last 12 months.

## 8-K filings

Material corporate events GeoVax Labs, Inc. New has disclosed to the SEC on Form 8-K.

- Nov 19, 2026 · Executive compensation change
  “Under the CFO Consulting Agreement, ... The Company will pay BPC $10,000 per month, plus applicable taxes ... BPC is eligible to receive a performance-based bonus ... and is eligible to participate in the Company's compensation, bonus incentive and equity-based compensation plans.”
- Nov 12, 2026 · Charter amendment
  “On November 10, 2026, GeoVax Labs, Inc. filed a Certificate of Amendment to our Certificate of Incorporation effecting a 1-for-24 reverse stock split. The rights and privileges of the holders of shares of Common Stock are substantially unaffected by the Reverse Stock Split.”
- Nov 9, 2026 · Executive officer appointment
  “Effective November 8, 2026, the Board of Directors appointed Tyler O'Brien as interim Chief Executive Officer. Until a permanent principal executive officer is appointed or designated, Mr. O'Brien will perform the functions of principal executive officer.”
- Nov 6, 2026 · [Ceo departure](https://massive.com/quote/sec-filings/8-k/ceo-departures.md)
  “On November 5, 2026, David A. Dodd was terminated as President and Chief Executive Officer of the GeoVax Labs, Inc. (the "Company"), effective immediately. Mr. Dodd remains a director of the Company and the Chairman of the Board of Directors.”
- Oct 27, 2026 · Director appointment
  “The remaining members of the Company's Board of Directors appointed three individuals designated by the Lender, Steven Brown, Tyler O'Brien and Manpreet Uppal as directors. The Lender Board Nominees constitute three of the five members of the Board of Directors and a majority of each of its committees.”

## Dividend history and stock splits

GeoVax Labs, Inc. New's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-24 · Nov 11, 2026
- 1-for-25 · Jan 12, 2026
- 1-for-15 · Jan 31, 2024

## GOVX short interest

How heavily GOVX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 175.9K |
| Avg volume | 184.19K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## GOVX news

The latest news and headlines about GeoVax Labs, Inc. New (GOVX).

- [Is Co-Diagnostics National Security’s Next Diagnostic Pick?](https://www.investing.com/analysis/is-codiagnostics-national-securitys-next-diagnostic-pick-200681113) · Investing.com · May 28, 2026 · positive sentiment
- [WHO Africa Chief Warns It's A 'Big Mistake' To Underestimate Ebola Outbreak As Deadly Virus Spreads Beyond Congo](https://www.benzinga.com/news/health-care/26/05/52761718/who-africa-chief-warns-its-a-big-mistake-to-underestimate-ebola-outbreak-as-deadly-virus-spreads?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · May 22, 2026 · positive sentiment
- [GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats](https://www.benzinga.com/trading-ideas/movers/26/05/52700723/geovax-stock-higher-as-company-highlights-mva-platform-for-ebola-threats?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · May 20, 2026 · positive sentiment
- [Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities](https://www.benzinga.com/pressreleases/25/07/n46457093/cancer-pipeline-milestones-coming-fast-as-regulators-revisit-research-priorities) · Benzinga · Jul 16, 2025 · positive sentiment
- [Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream](https://www.globenewswire.com/news-release/2025/07/16/3116247/0/en/Presenting-on-Emerging-Growth-Conference-84-Day-2-on-July-17-Register-to-live-stream.html) · GlobeNewswire Inc. · Jul 16, 2025 · neutral sentiment

## About GeoVax Labs, Inc. New

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 19 |
| Listed | Feb 1, 1995 |

[Company website](https://www.geovax.com)

## FAQ

### What is the GeoVax Labs, Inc. New (GOVX) stock price today?

GeoVax Labs, Inc. New (GOVX) is trading at $1.81 (-5.24% on the day) as of 7:59:59 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is GeoVax Labs, Inc. New?

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.

### What is the short interest in GOVX?

As of Oct 30, 2026, GOVX has 175.9K shares short and 1.0 days to cover.

### What exchange is GOVX listed on?

GeoVax Labs, Inc. New (GOVX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time GOVX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GOVX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [GeoVax Labs, Inc. New (GOVX) insider trading](https://massive.com/quote/govx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
